Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q3 | Oct 29, 2025 | Vergent Asset Management LLP | - | - | AMRT IJ, BCG LN, HDB VN, HIK LN, IDHC LN, KGRB MK | demographics, emerging markets, policy reform, stock selection, valuation | The commentary centers on frontier and emerging markets benefiting from demographic growth, policy reform, and improving corporate fundamentals. Country-level dispersion and idiosyncratic stock selection drive returns more than global macro factors. Valuation support and structural growth provide a favorable backdrop despite geopolitical noise. | View | |
| 2025 Q3 | Oct 24, 2025 | Diamond Hill International | 6.5% | 23.6% | BABA, HDB, HIK LN, ITUB4 BZ, KRN GR, SGX SP, TSM, WISE LN | AI, emerging markets, gold, Governance, Japan | The fund benefited from Asia-led gains and emphasizes opportunities in Japans governance reforms, AI-linked semiconductors, and select emerging market banks. Managers added exposure to gold producers as a hedge against political risk and inflation. They maintain focus on intrinsic value and capital discipline amid shifting trade and tariff dynamics. | HIK FRAN TSM |
View |
| 2025 Q3 | Oct 1, 2025 | Vela International Fund | 7.4% | - | 0AAL LN, COA LN, FEVR LN, GLOB, HIK LN | gold, Hedges, inflation, Miners, reserves | Gold and gold miners continue to act as portfolio insurance against inflation, credit destruction, and declining confidence in central bank independence. The letter argues that geopolitical shifts, fiscal dominance, and rising global reserve allocation to gold structurally support higher prices. Gold remains a strategic hedge and a return driver through high-quality miners with disciplined capital allocation. | GLOB COA LN FEVR LN TECN SW HIK LN |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Nov 28, 2025 | Fund Letters | Bob Sharpe | Hikma Pharmaceuticals PLC | Health Care | Pharmaceuticals | Bull | NYSE | Capacity, Generics, Injectables, Margins, tariffs | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||